UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003947
Receipt number R000004754
Scientific Title Evaluation of eicosapentaenoic acid (EPA) for preventing the progression of coronary atherosclerosis and revascularization in patients with dyslipidemia who underwent percutaneous coronary intervention (PCI)
Date of disclosure of the study information 2010/07/26
Last modified on 2010/07/28 10:51:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of eicosapentaenoic acid (EPA) for preventing the progression of coronary atherosclerosis and revascularization in patients with dyslipidemia who underwent percutaneous coronary intervention (PCI)

Acronym

Evaluation of EPA for preventing the progression of coronary sclerosis and revascularization in post-PCI patients with dyslipidemia

Scientific Title

Evaluation of eicosapentaenoic acid (EPA) for preventing the progression of coronary atherosclerosis and revascularization in patients with dyslipidemia who underwent percutaneous coronary intervention (PCI)

Scientific Title:Acronym

Evaluation of EPA for preventing the progression of coronary sclerosis and revascularization in post-PCI patients with dyslipidemia

Region

Japan


Condition

Condition

Coronary artery disease with dyslipidemia

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the prevention of progression of coronary atherosclerosis and coronary revascularization rate in non-PCI lesions and major adverse cardiovascular and cerebrovascular event (MACCE) in post-PCI patients with coronary artery diseases combining dyslipidemia by using strong statin alone or strong statin plus EPA

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

In non-PCI lesions with >= 50% stenosis according to the AHA classification,
1) change in MLD during the follow-up period
2) coronary revascularization

Key secondary outcomes

MACCE:
death, nonfatal myocardial infarction, cerebral accident, unstable angina requiring hospitalization


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

strong statin alone

Interventions/Control_2

strong statin plus EPA 1800mg daily

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1) Post-PCI patients with chronic coronary artery disease or acute coronary syndrome patients having >= 75% coronary artery stenosis according to the ACC/AHA classification
2) Patients with hypercholesterolemia taking strong statin or those meeting one of the dyslipidemia criteria: LDL-C >= 100mg/dl. TG >= 150mg/dl, HDL-C < 40mg/dl
3) Age: 20<=, < 75 years
4) Patients who can be followed up for longer than 18 months after PCI
5) Patients who have given written informed consent

Key exclusion criteria

1) Patients who have hypersensitivity to EPA
2) Patients who had cerebral accident in the past 6 months
3) Pregnant women and women suspected of being pregnant
4) Patients with gastrointestinal ulcer in active phase
5) Patients with bleeding
6) Patients who have very poor choleresis or severe liver dysfunction
7) Patients who are ineligible for this study
8) Patients with severe renal dysfunction or undergoing dialysis

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazusige Kadota

Organization

Kurashiki central Hospital

Division name

Department of Cardiology

Zip code


Address

1-1-1 Miwa, kurashik, Okayama 710-8602,Japan

TEL

+81-86-422-0210

Email



Public contact

Name of contact person

1st name
Middle name
Last name Yasushi Fuku

Organization

Kurashiki central Hospital

Division name

Department of Cardiology

Zip code


Address

1-1-1 Miwa, kurashik, Okayama 710-8602,

TEL

+81-86-422-0210

Homepage URL


Email



Sponsor or person

Institute

Kurashiki central Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

倉敷中央病院(岡山県)


Other administrative information

Date of disclosure of the study information

2010 Year 07 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2010 Year 03 Month 24 Day

Date of IRB


Anticipated trial start date

2010 Year 08 Month 01 Day

Last follow-up date

2013 Year 04 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 07 Month 26 Day

Last modified on

2010 Year 07 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004754


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name